One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients.

被引：0
|
作者：
Torres, A
De Broe, ME
D'Haese, PC
Hutchison, A
Jones, C
机构：
[1] Univ Canaries Hosp, Dept Nephrol, Tenerife, Spain
[2] Univ Antwerp, Dept Nephrol, B-2020 Antwerp, Belgium
[3] Manchester Royal Infirm, Inst Nephrol & Transplantat, Manchester M13 9WL, Lancs, England
[4] Shire Pharmaceut Grp Plc, Basingstoke, Hants, England
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：764A / 764A
页数：1
相关论文
共 50 条
  • [11] An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis
    Anna Wasilewska
    Rose Ann Murray
    Aimee Sundberg
    Sharif Uddin
    Heinrich Achenbach
    Aleksey Shavkin
    Tamás Szabó
    Andrea Vergani
    Obi Umeh
    BMC Nephrology, 23
  • [12] Comparative study of the effects of lanthanum carbonate and calcium carbonate on renal bone disease in patients on dialysis over 1 year.
    D'Haese, PC
    De Broe, ME
    Webster, I
    Spasovski, GB
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S394 - S394
  • [13] One-year open-label efficacy and safety of opicapone in Parkinson's disease BIPARK-II study
    Costa, R.
    Oliveira, C.
    Pinto, R.
    Lopes, N.
    Nunes, T.
    Rocha, J. -F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2014, 29 : S233 - S233
  • [14] One-year open-label study of entacapone in patients with advanced Parkinson disease
    Ahn, Tae-Beom
    Im, Joo-Hyuk
    Lee, Myoung Chong
    Vim, Jae Woo
    Lee, Won Yong
    Jeon, Beom S.
    JOURNAL OF CLINICAL NEUROLOGY, 2007, 3 (02): : 82 - 85
  • [15] One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study
    Schrezenmeier, Hubert
    Kulasekararaj, Austin
    Mitchell, Lindsay
    Sicre de Fontbrune, Flore
    Devos, Timothy
    Okamoto, Shinichiro
    Wells, Richard
    Rottinghaus, Scott T.
    Liu, Peng
    Ortiz, Stephan
    Lee, Jong Wook
    Socie, Gerard
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [16] One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies -
    Hirayama, Atsushi
    Yamashita, Shizuya
    Inomata, Hyoe
    Kassahun, Helina
    Cyrille, Marcoli
    Ruzza, Andrea
    Yoshida, Masayuki
    Kiyosue, Arihiro
    Ma, Yuhui
    Teramoto, Tamio
    CIRCULATION JOURNAL, 2017, 81 (07) : 1029 - +
  • [17] Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia:: A 6-month, randomized, comparative trial versus calcium carbonate
    Hutchison, AJ
    Maes, B
    Vanwalleghem, J
    Asmus, G
    Mohamed, E
    Schmieder, R
    Backs, W
    Jamar, R
    Vosskühler, A
    NEPHRON CLINICAL PRACTICE, 2005, 100 (01): : C8 - C19
  • [18] Multicenter Study on the Long-Term (3-Year) Efficacy of Lanthanum Carbonate in Dialysis Patients
    Ando, Ryoichi
    Yama, Satomi
    Ohnishi, Tsuyoshi
    Iwamoto, Shunsuke
    Kimura, Hitoshi
    Chida, Yoshiko
    Ishida, Yuji
    Yamada, Kouei
    Inagaki, Yuichiro
    Takayama, Masanobu
    Tachibana, Ken
    Kikuchi, Kan
    Inoue, Atsushi
    Ohtsuka, Masakazu
    THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 : 2 - 8
  • [19] A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis
    Finn, WF
    Joy, MS
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (05) : 657 - 664
  • [20] Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
    Faries, Douglas E.
    Ascher-Svanum, Haya
    Nyhuis, Allen W.
    Kinon, Bruce J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1399 - 1405
12345